Make a gift before the end of the year to drive research breakthroughs in 2026. 

Search

This is a podcast for neuroendocrine cancer patients and caregivers that presents expert information and patient perspectives.

V4 Professional Plus 4.0.23.21468 !new! - Prepar3d

Included high-fidelity models like the updated F-22 Raptor, F-35A, and various Sikorsky MH-60 variants.

: Combat-ready aircraft like the F-16 arrived with functional weapons, countermeasures (flares), and sensor views that respond to material temperatures. Prepar3D v4 Professional Plus 4.0.23.21468

refers to the initial release version of Lockheed Martin's fourth-generation flight simulation platform, specifically under its most advanced commercial and military license. Launched on May 30, 2017 , this version marked a transformative shift for the series by moving to a 64-bit architecture , which effectively eliminated the "Out-of-Memory" (OOM) crashes that plagued previous 32-bit iterations. Core Technical Advancements Included high-fidelity models like the updated F-22 Raptor,

: Users could load high-resolution 4K textures and complex third-party add-ons without exceeding the 3.2 GB memory limit of older systems. Launched on May 30, 2017 , this version

This is the of Prepar3D v4 (the first 64-bit generation), not an update or hotfix. The build number 21468 identifies this specific compilation.

needed to run this high-fidelity simulator, or are you interested in the latest updates from the newer v6 release? License Options - Prepar3D

Subscribe to our podcast:

Sign up to have NETRF notify you of the next NETWise podcast. Or, find and subscribe to NETWise on your favorite podcast service. 

Medical Disclaimer: This podcast is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information found here with their oncologist, physician, and/or appropriate qualified health professional. Listening to this podcast does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient’s oncologist, physician, or appropriate qualified health professional.